These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 32533190)
1. Characteristics of genomic alterations in Chinese cholangiocarcinoma patients. Jiang G; Zhang W; Wang T; Ding S; Shi X; Zhang S; Shi W; Liu A; Zheng S Jpn J Clin Oncol; 2020 Sep; 50(10):1117-1125. PubMed ID: 32533190 [TBL] [Abstract][Full Text] [Related]
2. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients. Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profile of cholangiocarcinomas in China. Tian W; Hu W; Shi X; Liu P; Ma X; Zhao W; Qu L; Zhang S; Shi W; Liu A; Cao J Oncol Lett; 2020 Apr; 19(4):3101-3110. PubMed ID: 32256810 [TBL] [Abstract][Full Text] [Related]
11. Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma. You HL; Huang WT; Liu TT; Weng SW; Eng HL Exp Mol Pathol; 2017 Dec; 103(3):249-254. PubMed ID: 29122566 [TBL] [Abstract][Full Text] [Related]
12. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226 [TBL] [Abstract][Full Text] [Related]
14. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study. Zhang C; You X; Zhang Q; Wang D Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978 [TBL] [Abstract][Full Text] [Related]
15. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729 [TBL] [Abstract][Full Text] [Related]
17. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077 [TBL] [Abstract][Full Text] [Related]
18. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma. Parasramka M; Yan IK; Wang X; Nguyen P; Matsuda A; Maji S; Foye C; Asmann Y; Patel T Mol Cancer; 2017 Jan; 16(1):22. PubMed ID: 28122578 [TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002 [TBL] [Abstract][Full Text] [Related]